Literature DB >> 17508035

Axonal loss and neuroprotection in optic neuropathies.

Leonard A Levin1.   

Abstract

Most optic neuropathies do not have effective treatments. Examples are ischemic optic neuropathy, Leber hereditary optic neuropathy, optic neuritis, and traumatic optic neuropathy. In some cases, the pathophysiology of the optic nerve injury is not fully understood. For example, while the demyelinative aspects of optic neuritis have been studied, the mechanism by which the axonal loss occurs is less apparent. In other cases, although the pathophysiology of the optic neuropathy may be understood, there is difficulty treating the disease, for example, with traumatic optic neuropathy. In response to this therapeutic dearth, the concept of neuroprotection has arisen. Neuroprotection is a therapeutic paradigm for preventing death of neurons from injury and maintaining function. In optic neuropathies, the corresponding neuron is the retinal ganglion cell. These cells are unable to divide, and optic neuropathies irrevocably result in their death; therefore, the primary target of neuroprotection are retinal ganglion cells and their axons. This review emphasizes that most optic neuropathies are axonal and thus good targets for neuroprotection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17508035     DOI: 10.3129/can j ophthalmol.i07-046

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  20 in total

Review 1.  The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market.

Authors:  Ricardo Titze-de-Almeida; Catherine David; Simoneide Souza Titze-de-Almeida
Journal:  Pharm Res       Date:  2017-04-07       Impact factor: 4.200

2.  Visual and anatomical outcomes of non-arteritic anterior ischemic optic neuropathy with high-dose systemic corticosteroids.

Authors:  Gema Rebolleda; Marta Pérez-López; Pilar Casas-LLera; Inés Contreras; Francisco José Muñoz-Negrete
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-03-24       Impact factor: 3.117

3.  Should steroids be offered to patients with nonarteritic anterior ischemic optic neuropathy?

Authors:  Andrew G Lee; Valérie Biousse
Journal:  J Neuroophthalmol       Date:  2010-06       Impact factor: 3.042

4.  Protective effects of 7,8-dihydroxyflavone on retinal ganglion and RGC-5 cells against excitotoxic and oxidative stress.

Authors:  Vivek K Gupta; Yuyi You; Jonathan C Li; Alexander Klistorner; Stuart L Graham
Journal:  J Mol Neurosci       Date:  2012-10-07       Impact factor: 3.444

5.  Levodopa as a possible treatment of visual loss in nonarteritic anterior ischemic optic neuropathy.

Authors:  Deanna P Lyttle; Lenworth N Johnson; Edward A Margolin; Richard W Madsen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-10-20       Impact factor: 3.117

6.  Long-term evaluation of Leber's hereditary optic neuropathy-like symptoms in rotenone administered rats.

Authors:  Li Zhang; Laura Liu; Ann L Philip; Juan C Martinez; Juan C Guttierez; Mathieu Marella; Gaurav Patki; Akemi Matsuno-Yagi; Takao Yagi; Biju B Thomas
Journal:  Neurosci Lett       Date:  2014-12-03       Impact factor: 3.046

Review 7.  Treatment of nonarteritic anterior ischemic optic neuropathy.

Authors:  Edward J Atkins; Beau B Bruce; Nancy J Newman; Valérie Biousse
Journal:  Surv Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 6.048

Review 8.  Post-traumatic visual loss.

Authors:  Edward J Atkins; Nancy J Newman; Valérie Biousse
Journal:  Rev Neurol Dis       Date:  2008

9.  Virally delivered, constitutively active NFκB improves survival of injured retinal ganglion cells.

Authors:  Galina Dvoriantchikova; Steve Pappas; Xueting Luo; Marcio Ribeiro; Dagmara Danek; Daniel Pelaez; Kevin K Park; Dmitry Ivanov
Journal:  Eur J Neurosci       Date:  2016-09-13       Impact factor: 3.386

10.  Successful amelioration of mitochondrial optic neuropathy using the yeast NDI1 gene in a rat animal model.

Authors:  Mathieu Marella; Byoung Boo Seo; Biju B Thomas; Akemi Matsuno-Yagi; Takao Yagi
Journal:  PLoS One       Date:  2010-07-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.